CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today's drugs), CellVir's approach targets host-virus protein-protein interactions which have been shown to be